Receptor News and Research

RSS

Researchers identify a new mechanism for tumor control

The interaction of a ligand (Neurotrophine-3) and its dependence receptor (TrkC) constitutes a novel mechanism for tumor control in pediatric cancers such as neuroblastoma, and may also be important to the inhibition of other cancers such as breast cancer.

9 Mar 2010

Aton Pharma introduces authorized generic version of Timoptic-XE

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE.

9 Mar 2010

Abbott announces definitive agreement to acquire Facet Biotech

Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

9 Mar 2010

AssureRx Health adds CYP1A2 gene to laboratory-developed pharmacogenetic test

AssureRx Health, Inc., a personalized medicine company focused on pharmacogenetics to aid in the treatment of patients with psychiatric disorders, today announced that it has added a fifth gene, CYP1A2, to its laboratory-developed pharmacogenetic test.

9 Mar 2010

Novel interventions for New World hemorrhagic fevers needed

New World hemorrhagic fevers are emerging infectious diseases found in South America that can cause terrible, Ebola-like symptoms. Current treatments are expensive and only partially effective.

9 Mar 2010

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.

9 Mar 2010

Positive results from international study of Oncotype DX breast cancer RS

Genomic Health, Inc. today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer Recurrence Score® (RS) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive, postmenopausal breast cancer patients who are treated with either anastrozole or tamoxifen.

9 Mar 2010

Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals

Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.

8 Mar 2010

Sigma Life Science extends portfolio of knockout rat models with the release of ADME/Tox applications

Sigma® Life Science, an innovative brand of Sigma-Aldrich®, today extended its portfolio of knockout rat models with the announcement of a new suite of models designed to facilitate more predictive absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) studies.

8 Mar 2010

Improvements needed in communicating cancer recurrence risks and treatment decisions with patients

A new study has found that one in three early-stage breast cancer patients who received genomic testing when deciding about treatment options felt they did not fully understand their discussions with physicians about their test results and their risk of recurrence. About one in four experienced distress when receiving their test results.

8 Mar 2010

Scientists show Ritalin boosts cognitive abilities by enhancing brain plasticity

Doctors treat millions of children with Ritalin every year to improve their ability to focus on tasks, but scientists now report that Ritalin also directly enhances the speed of learning.

8 Mar 2010

Scientists identify the role of vitamin D in activation of T cells

Scientists at the University of Copenhagen have discovered that Vitamin D is crucial to activating our immune defenses and that without sufficient intake of the vitamin, the killer cells of the immune system - T cells - will not be able to react to and fight off serious infections in the body.

8 Mar 2010

Engineers built sensor array that can detect single molecules of hydrogen peroxide

MIT chemical engineers have built a sensor array that, for the first time, can detect single molecules of hydrogen peroxide emanating from a single living cell.

7 Mar 2010

Thymosin beta 4 improves neurological functional outcome

REGENERX BIOPHARMACEUTICALS, INC. announced that a research team from the Henry Ford Hospital in Detroit, MI reported that Thymosin beta 4 (Tβ4), administered to rats one day after embolic stroke, improved neurological functional outcome compared to control animals.

6 Mar 2010

Signaling mechanisms responsible for HGF-induced CCA invasiveness: More insight

Cholangiocarcinoma (CCA), a bile duct cancer, is one of the major cancers in Northeast Thailand. This cancer is difficult to diagnose and has high metastatic and mortality rates. Overexpression of Met, a hepatocyte growth factor (HGF) receptor, has frequently been found in CCA and is correlated with progression of this type of cancer.

5 Mar 2010

Kyto Biopharma signs licensing agreement with RFSUNY, gains patent rights to Transcobalamin Receptor

Kyto Biopharma Inc., is pleased to announce that it has signed a licensing agreement with the Research Foundation of the State University of New York. The licensing agreement grants Kyto patent rights to the Transcobalamin (Vitamin B12) Receptor and to an additional broad group of other patents which are critical to Kyto’s research and development strategy for the treatment of cancer.

5 Mar 2010

Acupuncture may reduce joint pain and stiffness caused by routine breast cancer therapy

A new study, led by researchers at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center, demonstrates that acupuncture may be an effective therapy for joint pain and stiffness in breast cancer patients who are being treated with commonly used hormonal therapies. Results were published in the Journal of Clinical Oncology.

4 Mar 2010

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. Celldex reported a net loss of $13.5 million, or $0.43 per share, for the fourth quarter of 2009 compared to a net loss of $7.5 million, or $0.47 per share, for the fourth quarter of 2008.

4 Mar 2010

Brain study may lead to new forms of treatment for Alzheimer's disease

A study from EPFL's (Ecole Polytechnique F-d-rale de Lausanne) Laboratory of Neuroenergetics and Cellular Dynamics in Lausanne Switzerland, published today in the Journal of Neuroscience, may lead to new forms of treatment following a better understanding of how Amyloid-Beta found in cerebral plaques, typically present in the brain of Alzheimer's patients, may lead to neurodegeneration.

4 Mar 2010

Severe inflammatory diseases: Blocking "death messenger" might be a promising treatment

The signaling molecule CD95L, known as "death messenger," causes an inflammatory process in injured tissue after spinal cord injuries and prevents its healing. This discovery was published by scientists of the German Cancer Research Center. In mice, the researchers found out that if they switch off CD95L, the injured spinal cord heals and the animals regain better ability to move. Therefore, substances which block the death messenger might offer a new approach in the treatment of severe inflammatory diseases.

4 Mar 2010

Receptor News and Research

Researchers identify a new mechanism for tumor control

Aton Pharma introduces authorized generic version of Timoptic-XE

Abbott announces definitive agreement to acquire Facet Biotech

AssureRx Health adds CYP1A2 gene to laboratory-developed pharmacogenetic test

Novel interventions for New World hemorrhagic fevers needed

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Positive results from international study of Oncotype DX breast cancer RS

Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals

Sigma Life Science extends portfolio of knockout rat models with the release of ADME/Tox applications

Improvements needed in communicating cancer recurrence risks and treatment decisions with patients

Scientists show Ritalin boosts cognitive abilities by enhancing brain plasticity

Scientists identify the role of vitamin D in activation of T cells

Engineers built sensor array that can detect single molecules of hydrogen peroxide

Thymosin beta 4 improves neurological functional outcome

Signaling mechanisms responsible for HGF-induced CCA invasiveness: More insight

Kyto Biopharma signs licensing agreement with RFSUNY, gains patent rights to Transcobalamin Receptor

Acupuncture may reduce joint pain and stiffness caused by routine breast cancer therapy

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Brain study may lead to new forms of treatment for Alzheimer's disease

Severe inflammatory diseases: Blocking "death messenger" might be a promising treatment

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News